- Home
- NGNE
NGNE
Neurogene Inc.
as 11-07-2024 3:35pm EST
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 471.1M | IPO Year: | N/A |
| Target Price: | $49.00 | AVG Volume (30 days): | 166.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.49 - $73.59 | Next Earning Date: | 11-15-2024 |
| Revenue: | $925,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Neurogene Inc. News
NGNE Breaking Stock News: Dive into NGNE Ticker-Specific Updates for Smart Investing
TipRanks
3 days ago
Neurogene Secures $200M for Genetic Therapy Development
Business Wire
4 days ago
Neurogene Announces Oversubscribed $200 Million Private Placement
Business Wire
18 days ago
Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Simply Wall St.
3 months ago
Neurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You Think
Business Wire
3 months ago
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
Business Wire
3 months ago
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
Business Wire
4 months ago
Neurogene to Participate in BMO Genetic Medicines Summit
Business Wire
4 months ago
Neurogene Announces Addition to Russell 3000® Index
Compare NGNE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NGNE Neurogene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.